PE20130690A1 - Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato - Google Patents

Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato

Info

Publication number
PE20130690A1
PE20130690A1 PE2012001383A PE2012001383A PE20130690A1 PE 20130690 A1 PE20130690 A1 PE 20130690A1 PE 2012001383 A PE2012001383 A PE 2012001383A PE 2012001383 A PE2012001383 A PE 2012001383A PE 20130690 A1 PE20130690 A1 PE 20130690A1
Authority
PE
Peru
Prior art keywords
metotrexate
rheumatoid arthritis
treatment
laquinimod
combination
Prior art date
Application number
PE2012001383A
Other languages
English (en)
Inventor
Eran Tarcic
Nora Tarcic
Joel Kaye
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44531858&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130690(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PE20130690A1 publication Critical patent/PE20130690A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN METODO DE TRATAMIENTO DE LA ARTRITIS REUMATOIDE QUE COMPRENDE ADMINISTRAR ORALMENTE i) LAQUINIMOD SODIO EN UNA CANTIDAD DE 0.0005 A 10 MG/KG/DIA; ii) METOTREXATO EN UNA CANTIDAD DE 0.02 A 1.0 MG/KG/DIA; Y ADEMAS iii) ADMINISTRAR FARMACOS ANTIINFLAMATORIOS NO ESTEROIDALES, SALICILATOS, SULFASALAZINA, FARMACOS CITOTOXICOS, ANTICUERPOS INMUNOSUPRESORES, ENTRE OTROS. DICHO METODO DE TRATAMIENTO REDUCE LOS SINTOMAS ASOCIADOS CON ARTRITIS REUMATOIDE TALES COMO LA INFLAMACION, DANO AL CARTILAGO, RESORCION OSEA, PROTEINURIA Y ELIMINA LOS SEDIMENTOS URINARIOS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE LAQUINIMOD SODIO Y METOTREXATO
PE2012001383A 2010-03-03 2011-03-02 Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato PE20130690A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33937510P 2010-03-03 2010-03-03

Publications (1)

Publication Number Publication Date
PE20130690A1 true PE20130690A1 (es) 2013-07-07

Family

ID=44531858

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012001383A PE20130690A1 (es) 2010-03-03 2011-03-02 Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato

Country Status (21)

Country Link
US (1) US8501766B2 (es)
EP (1) EP2542079B1 (es)
JP (1) JP5819328B2 (es)
KR (1) KR20130014523A (es)
CN (2) CN105796556A (es)
AU (1) AU2011223697B2 (es)
BR (1) BR112012022187A2 (es)
CA (1) CA2791709A1 (es)
CL (1) CL2012002424A1 (es)
CO (1) CO6630085A2 (es)
DK (1) DK2542079T3 (es)
EA (1) EA201290860A1 (es)
ES (1) ES2476368T3 (es)
MX (1) MX2012010066A (es)
NZ (1) NZ602478A (es)
PE (1) PE20130690A1 (es)
PT (1) PT2542079E (es)
SG (1) SG183513A1 (es)
SI (1) SI2542079T1 (es)
WO (1) WO2011109531A1 (es)
ZA (1) ZA201207128B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2523762T3 (es) * 2005-10-19 2014-12-01 Teva Pharmaceutical Industries Ltd Cristales de laquinimod sódico, y procedimientos para su fabricación
RS52169B (en) 2006-06-12 2012-08-31 Teva Pharmaceutical Industries Limited STABLE LAKVINIMOD PREPARATIONS
PL2682120T3 (pl) 2007-12-20 2017-02-28 Teva Pharmaceutical Industries, Ltd. Stabilne preparaty lakwinimodu
ES2633658T3 (es) * 2008-09-03 2017-09-22 Teva Pharmaceutical Industries Ltd. Moduladores 2-oxo-1,2-dihidro-quinolina de la función inmunitaria
NZ597378A (en) * 2009-06-19 2014-08-29 Teva Pharma Treatment of multiple sclerosis with laquinimod
DK2458992T3 (en) * 2009-07-30 2016-02-08 Teva Pharma Treatment of crohn's disease with laquinimod
SI2467372T1 (sl) 2009-08-10 2016-09-30 Teva Pharmaceutical Industries Ltd. Zdravljenje motenj, povezanih z BDNF, z uporabo lakvinimoda
PE20130613A1 (es) * 2010-03-03 2013-06-23 Teva Pharma Tratamiento de lupus nefritis usando laquinimod
AU2011274496B2 (en) 2010-07-09 2016-03-10 Teva Pharmaceutical Industries Ltd. Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
JP2014530821A (ja) 2011-10-12 2014-11-20 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療
EA201491460A1 (ru) 2012-02-03 2015-01-30 Тева Фармасьютикал Индастриз Лтд. ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CA2890194A1 (en) 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Amine salts of laquinimod
JP2016513665A (ja) 2013-03-14 2016-05-16 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドの経皮製剤
TW201519892A (zh) 2013-03-14 2015-06-01 Teva Pharma 拉喹莫德鈉之結晶及其製造之改良方法
CN106573014A (zh) 2014-04-29 2017-04-19 梯瓦制药工业有限公司 用于治疗具有高残疾状况的复发‑缓解型多发性硬化症(rrms)的患者的拉喹莫德
CN115281149A (zh) * 2021-05-12 2022-11-04 四川大学华西医院 一种临床前类风湿关节炎(Pre-RA)小鼠模型

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (fr) 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5912349A (en) 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
CN100390148C (zh) 1999-10-25 2008-05-28 活跃生物技术有限公司 用于治疗恶性肿瘤的药物
WO2002007757A2 (en) 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US6307050B1 (en) 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US7560557B2 (en) 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US20070292461A1 (en) 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
JP2007524626A (ja) * 2003-06-25 2007-08-30 エラン ファーマシューティカルズ，インコーポレイテッド 関節リウマチを治療する方法および組成物
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
CA2561164A1 (en) 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and their use
US20090048181A1 (en) 2004-09-02 2009-02-19 Schipper Hyman M Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
PL1797109T3 (pl) 2004-09-09 2016-11-30 Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
KR20140077946A (ko) 2005-10-13 2014-06-24 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
ES2523762T3 (es) 2005-10-19 2014-12-01 Teva Pharmaceutical Industries Ltd Cristales de laquinimod sódico, y procedimientos para su fabricación
PL1951674T3 (pl) * 2005-10-26 2012-04-30 Merck Serono Sa Pochodne sulfonamidowe i ich zastosowania do modulowania metaloproteinaz
US20080108641A1 (en) 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en) 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
PL2676967T3 (pl) 2006-02-28 2019-12-31 Biogen Ma Inc. Metody leczenia chorób zapalnych i autoimmunologicznych za pomocą natalizumabu
JP2009531304A (ja) 2006-02-28 2009-09-03 エラン ファーマシューティカルズ，インコーポレイテッド α−４阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法
ES2663377T3 (es) 2006-03-03 2018-04-12 Biogen Ma Inc. Métodos para el tratamiento de enfermedades inflamatorias y autoinmunes con natalizumab
EP2010214A4 (en) * 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
WO2007139887A2 (en) 2006-05-22 2007-12-06 Cargill, Incorporated Methods for treating bone or joint inflammation
US20080118553A1 (en) 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
RS52169B (en) 2006-06-12 2012-08-31 Teva Pharmaceutical Industries Limited STABLE LAKVINIMOD PREPARATIONS
ATE510538T1 (de) 2006-08-11 2011-06-15 Univ Johns Hopkins Zusammensetzungen und verfahren für nervenschutz
CN101743018A (zh) 2006-12-19 2010-06-16 梅里麦克药品公司 甲胎蛋白和免疫调谐剂的共同施用以治疗多发性硬化
WO2008085484A2 (en) 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
WO2009009529A1 (en) 2007-07-11 2009-01-15 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
PL2682120T3 (pl) 2007-12-20 2017-02-28 Teva Pharmaceutical Industries, Ltd. Stabilne preparaty lakwinimodu
ES2633658T3 (es) 2008-09-03 2017-09-22 Teva Pharmaceutical Industries Ltd. Moduladores 2-oxo-1,2-dihidro-quinolina de la función inmunitaria
EP2370436A1 (en) 2008-11-13 2011-10-05 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
NZ597378A (en) 2009-06-19 2014-08-29 Teva Pharma Treatment of multiple sclerosis with laquinimod
DK2458992T3 (en) 2009-07-30 2016-02-08 Teva Pharma Treatment of crohn's disease with laquinimod
SI2467372T1 (sl) 2009-08-10 2016-09-30 Teva Pharmaceutical Industries Ltd. Zdravljenje motenj, povezanih z BDNF, z uporabo lakvinimoda
PE20130613A1 (es) 2010-03-03 2013-06-23 Teva Pharma Tratamiento de lupus nefritis usando laquinimod
SG10201501539SA (en) 2010-03-03 2015-04-29 Teva Pharma Treatment of lupus arthritis using laquinimod
AU2011274496B2 (en) 2010-07-09 2016-03-10 Teva Pharmaceutical Industries Ltd. Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
CN102985090B (zh) 2010-07-09 2014-11-26 泰华制药工业有限公司 5-氯-4-羟基-1-甲基-2-氧代-n-苯基-1,2-二氢喹啉-3-甲酰胺、其盐和用途
MX2013006464A (es) 2010-12-07 2013-07-29 Teva Pharma Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple.
CN105944081A (zh) 2011-07-28 2016-09-21 泰华制药工业有限公司 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
SG10201606204TA (en) 2011-07-28 2016-09-29 Teva Pharma Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Interferon-Beta

Also Published As

Publication number Publication date
AU2011223697A1 (en) 2012-10-11
CO6630085A2 (es) 2013-03-01
DK2542079T3 (da) 2014-08-25
ES2476368T3 (es) 2014-07-14
EP2542079A1 (en) 2013-01-09
SI2542079T1 (sl) 2014-08-29
JP2013521304A (ja) 2013-06-10
NZ602478A (en) 2014-09-26
CL2012002424A1 (es) 2012-12-21
WO2011109531A1 (en) 2011-09-09
KR20130014523A (ko) 2013-02-07
EA201290860A1 (ru) 2013-04-30
CN102781240A (zh) 2012-11-14
CN105796556A (zh) 2016-07-27
US8501766B2 (en) 2013-08-06
EP2542079A4 (en) 2013-07-24
JP5819328B2 (ja) 2015-11-24
EP2542079B1 (en) 2014-05-21
CA2791709A1 (en) 2011-09-09
AU2011223697B2 (en) 2016-07-14
PT2542079E (pt) 2014-07-18
BR112012022187A2 (pt) 2015-09-22
ZA201207128B (en) 2014-04-30
SG183513A1 (en) 2012-09-27
MX2012010066A (es) 2012-10-03
US20110218203A1 (en) 2011-09-08

Similar Documents

Publication Publication Date Title
PE20130690A1 (es) Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato
PE20130496A1 (es) Tratamiento de artritis por lupus usando laquinimod
PE20121136A1 (es) Composiciones de pelicula sublinguales y bucales
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
NZ599847A (en) Pharmaceutical composition comprising a glp-1 agonist and methionine
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201200763A1 (ru) Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep
MY158504A (en) Fatty acid niacin conjugates and their uses
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
MX2012003082A (es) Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol.
EA201390840A1 (ru) Полициклический lpaантагонист и его применение
ECSP109905A (es) Moduladores de receptor 7 tipo toll
MX2010007083A (es) Combinacion anti-retroviral.
EA200870448A1 (ru) Тризамещенные 1,2,4-триазолы
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
MX2013000694A (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
MA31706B1 (fr) Formulations galéniques de composés organiques
ECSP067074A (es) Derivados de 4-fenil-pirimidina-2-carbonitrilo
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
CL2011002213A1 (es) Sal de adicion cristalina de (i) trometamina con (ii) un derivado de acido azabifenilaminobenzoico; composicion farmaceutica que comprende a la sal y otros agentes terapeuticos; combinacion farmaceutica; y su uso para el tratamiento de artritis reumatoide, artritis psoriasica, espondilitis anquilosante, esclerosis multiple, entre otras
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.
EP2611799A4 (en) PHARMACEUTICAL COMPOSITIONS OF LINEZOLID

Legal Events

Date Code Title Description
FC Refusal